Dear Dennis, Joga, Naoto-san and All Dennis, I fully agree with your two comments .
Concerning my mail, I should have written: the abstract "corrected by clinicians challenging **up to** the last comma and p-value." Which means they did much more than looking at commas, which by the end greatly improved the abstract. They valued the work, care about science, wanted to understand and by the end improved the abstract to give it all chances. I fully concur also with Joga and believe this is the path to follow. Kind regards Pascal Envoy? de mon iPhone Le 7 avr. 2016 ? 19:11, Dennis Fisher <[email protected]<mailto:[email protected]>> a ?crit : I agree with Phil. I have presented recently at two large endocrine meetings, one in the US, one in Europe. In both cases, I took complicated PK/PD models and kept it simple, emphasizing how the models could / would be used in clinical development and clinical practice. The response at both meetings was excellent - lots of people expressing interest in the models (and, interestingly, two of the competitors to the company for which I was consulting tried to enlist my consulting help). And, I disagree with Nick's comment yesterday. Perhaps oncology clinicians are concerned about commas (I cannot speak to that issue) but I truly doubt Nick's claim that they don't care about science - the advances in oncology in recent years have been remarkable. Dennis Fisher MD P < (The "P Less Than" Company) Phone: 1-866-PLessThan (1-866-753-7784) Fax: 1-866-PLessThan (1-866-753-7784) www.PLessThan.com<http://www.plessthan.com/> On Apr 7, 2016, at 7:49 AM, Lowe, Phil <[email protected]<mailto:[email protected]>> wrote: I would echo Pascal's point. Getting pharmacometric work into large clinical conferences is not straightforward. It can be done (see link)http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note where I was in the author list as the sole modeller. It helps to work closely with the clinicians on the messaging. That said, it was fun at the meeting, explaining the data and model curves to clinicians with them asking how such knowledge could impact their patients. An eye-opener. Keep trying Naoto! All the best, Phil Philip J Lowe PhD Executive Director Pharmacometrics Scientist Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46 4056 Basel, Switzerland Phone: +41 61 324 4676 [email protected]<mailto:[email protected]> From: [email protected]<mailto:[email protected]> [mailto:[email protected]] On Behalf Of Pascal Girard Sent: 06 April 2016 10:39 To: Naoto Hayashi; [email protected]<mailto:[email protected]> Cc: nmusers Subject: RE: [NMusers] ASCO and pharmacometrics Dear Naoto, In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is our "champion" ! I got one accepted on model for Exp-Tumor Size - OS at European Cancer Congress 2013 . But I can tell you that a medical writer rewrote it entirely and it took 1 month to get it reviewed and corrected by clinicians challenging every comma and p-value. To give you an idea of the respective size of the meetings: ACOP N=500, PAGE N>600, ECC N> 10,000, ASCO N>20,000. So the advice I would give, is just improve the quality and readability of our abstract and it will make it. By readability, I mean show it to an oncologist clinician. If he does not understand, rewrite it with the help of a medical writer ... With best regards / Mit freundlichen Gr??en / Cordialement Pascal This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith. Click http://www.merckgroup.com/disclaimer to access the German, French, Spanish and Portuguese versions of this disclaimer.
